WO1993021193A1 - Platinum complex and antineoplastic agent - Google Patents
Platinum complex and antineoplastic agent Download PDFInfo
- Publication number
- WO1993021193A1 WO1993021193A1 PCT/JP1993/000483 JP9300483W WO9321193A1 WO 1993021193 A1 WO1993021193 A1 WO 1993021193A1 JP 9300483 W JP9300483 W JP 9300483W WO 9321193 A1 WO9321193 A1 WO 9321193A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- platinum
- platinum complex
- chondroitin
- csa
- monosulfate
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 186
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 93
- 239000002246 antineoplastic agent Substances 0.000 title claims description 9
- 229940034982 antineoplastic agent Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 23
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 21
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000000052 comparative effect Effects 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 6
- 241000283153 Cetacea Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- -1 alkali metal salt Chemical class 0.000 claims description 4
- QCDMSCUTQSXHCU-UHFFFAOYSA-N 1-(aminomethyl)cyclohexan-1-amine Chemical compound NCC1(N)CCCCC1 QCDMSCUTQSXHCU-UHFFFAOYSA-N 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- YKGDAMWMFVRGDH-UHFFFAOYSA-N 1-(aminomethyl)cyclopentan-1-amine Chemical group NCC1(N)CCCC1 YKGDAMWMFVRGDH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- DBBUVLSRTWYISN-UHFFFAOYSA-N cycloheptane-1,2-diamine Chemical compound NC1CCCCCC1N DBBUVLSRTWYISN-UHFFFAOYSA-N 0.000 claims description 2
- MVTAAUNISXMHJU-UHFFFAOYSA-N cyclooctane-1,2-diamine Chemical compound NC1CCCCCCC1N MVTAAUNISXMHJU-UHFFFAOYSA-N 0.000 claims description 2
- MYJQGGALXPHWLV-UHFFFAOYSA-N cyclopentane-1,2-diamine Chemical compound NC1CCCC1N MYJQGGALXPHWLV-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 5
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 description 19
- 150000003057 platinum Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 210000000845 cartilage Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229920001542 oligosaccharide Polymers 0.000 description 9
- 150000002482 oligosaccharides Chemical class 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229920002567 Chondroitin Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000966257 Homo sapiens Limb region 1 protein homolog Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100040547 Limb region 1 protein homolog Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920001284 acidic polysaccharide Polymers 0.000 description 2
- 150000004805 acidic polysaccharides Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- DYVFBWXIOCLHPP-UHFFFAOYSA-N chembl368427 Chemical compound N#CC=1C(N)=NC(C=2C(=CC=CC=2O)OCC2CC2)=CC=1C1CCNCC1 DYVFBWXIOCLHPP-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- ZUYYQGFCSKJGDO-UHFFFAOYSA-N 2-(aminomethyl)cyclohexan-1-amine Chemical compound NCC1CCCCC1N ZUYYQGFCSKJGDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 1
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000251729 Elasmobranchii Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- YDHFNPLALGFCFC-UHFFFAOYSA-L dichloroplatinum platinum Chemical compound Cl[Pt](Cl)[Pt] YDHFNPLALGFCFC-UHFFFAOYSA-L 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000001546 nitrifying effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- QMYDVDBERNLWKB-UHFFFAOYSA-N propane-1,2-diol;hydrate Chemical compound O.CC(O)CO QMYDVDBERNLWKB-UHFFFAOYSA-N 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
Definitions
- the present invention relates to a platinum complex useful as an antitumor agent and an antitumor agent containing the same as an active ingredient.
- Cisplatin is known as a typical platinum complex having antitumor activity (Nature, ⁇ , 385 (1969)). Although cisplatin has excellent antitumor activity against solid tumors, it has a problem that it has strong side effects such as nephrotoxicity.
- platinum complexes having various leaving groups have been synthesized.
- Compounds having a sugar acid such as glucuronic acid as the leaving group are also known (Japanese Patent Application Laid-Open No. 54-44620, Japanese Patent Publication No. 63-71194, Japanese Patent Publication No. 3-663). 1 8).
- cis-platinum (1,2-cyclohexanediamine) complexed with chondroitin sulfate is known (JP-A-59-116221).
- these compounds had insufficient antitumor activity even if the side effects were reduced, or were not sufficiently reduced.
- the present inventors have previously synthesized a platinum complex using an acid polysaccharide such as chondroitin sulfate or hyaluronic acid as a leaving group (carrier) and found that it has antitumor activity (particularly). Kaihei 2—1 3 5 2 0 1 No. 1).
- a platinum complex using chondroitin sulfate as a leaving group is soft Chondroitin sulfate (contains chondroitin-6-sulfate as the main component) obtained from bone is used, the platinum content is about 20% (W / W) or more, and the solubility in water is low (lmgZml Below).
- these platinum complexes have a lower antitumor effect, lower organ selectivity, and a higher release rate of platinum complexes into physiological saline compared to platinum complexes using hyaluronic acid as a leaving group. The half-life is expected to be short), and the toxicity was strong.
- An object of the present invention is to solve the above-mentioned problems of a conventional platinum complex containing an acidic polysaccharide, particularly chondroitin sulfate containing chondroitin 16-sulfuric acid as a main component, as a leaving group.
- the present invention provides a compound represented by the general formula (1):
- R 1 represents cycloalkanediamine having 3 to 8 carbon atoms
- the present invention provides an antitumor containing the platinum complex as an active ingredient. It provides an ulcer.
- the platinum complex of the present invention has a general formula (2)
- Cis-dihalogenosis-cycloalkanediamine platinum represented by the formula:
- cis-dihalogeno-trans-cycloalkanediamine platinum ( ⁇ ), or a mixture thereof (hereinafter, these are collectively referred to as cis-dihalogeno-cycloalkanediamine platinum (II)).
- Ii a diastereomeric form (aqua form; hydrate) and chondroitin sulfate (mainly chondroitin-14-sulfate) or its alkali salt in an aqueous medium such as water under light-shielding conditions (eg, in a dark room). Medium), slightly acidic to neutral (for example, pH 4.0 to 7.0), and a reaction temperature of 0 to 40 (for example, around room temperature) for several hours to several 10 days Can be.
- the cycloalkanediamine having 3 to 8 carbon atoms represented by R 1 includes 1,2-cyclopentanediamine, 1,2-cyclohexanediamine, and 1,2— Cycloheptanediamine, 1,2-cyclooctanediamine, 1-amino-1-aminomethylcyclopentane, 1-amino-1-aminomethylcyclohexane, 1-amino-2 -Aminomethylcyclohexane and the like are exemplified, and the halogen atom represented by X is exemplified by chlorine, bromine and fluorine.
- Examples of the diaco-form of cycloalkanediamineplatinum (II) as a raw material for the above-mentioned reaction include, for example, the above-mentioned cis-dihalogenocycloalkanediazine.
- Minplatinum ( ⁇ ) is converted into an aqueous solution or aqueous suspension, and preferably reacted with silver nitrate, silver sulfate, etc. under light-shielding conditions to cause nitrification (nitration) or sulfated (sulfated) and hydration.
- Known method for removing precipitated precipitates (silver octogenide) (JP-A-64-690; JP-T-Hei 2-500745); J. Am. Chem. Soc , 99, 120 (1973); Chera. Biol. Interactions., 26, 227 (1979).
- Min-platinum (II) may be brought into contact with an anion exchange resin (0H type), and nitrate may be substituted with a hydroxyl group (for example, Japanese Patent Publication No. 2-511918, Japanese Patent Publication No. 3-583 58 8 Reference).
- chondroitin, chondroitin sulfate or its alkali salt which is mainly composed of tin-4 monosulfate, is mainly used for cartilage (nose cartilage, tracheal cartilage, etc.) of mammals such as whales, cattle, horses, sheep, and pigs. ) Is extracted and purified according to a conventional method, and in the present invention, 50% or more thereof is chondroitin-14-monosulfate.
- Chondroitin sulfate containing chondroitin-14-monosulfate also referred to as chondroitin sulfate A
- chondroitin sulfate A which is a component of the platinum complex of the present invention, is described in Japanese Patent Application Laid-Open No.
- chondroitin sulfate prepared mainly from cartilage of teleost fish such as sharks and rays
- chondroitin-6-sulfate also called chondroitin sulfate C
- chondroitin sulfate containing as its main component chondroitin-14-monosulfate used in the present invention.
- Chondroitin-4 monosulfate is preferably an alkali metal salt such as a sodium salt, a potassium salt, or a lithium salt.
- platinum complex of the present invention in a solution state can be collected.
- This platinum complex solution is treated in accordance with a standard method for pulverizing a water-soluble polysaccharide, such as freeze-drying, drying under reduced pressure, spray-drying, and precipitation using an organic solvent (alcohol, acetate, etc.). It is also possible to collect the platinum complex of the present invention in a form.
- a carboxyl group and / or a sulfate group of chondroitin-14-monosulfate is added to the cycloalkanediamineplatinum (II) residue represented by the general formula (1).
- Coordinated complex which is electrophoretically uniform and has a platinum content of 5% by weight or less, preferably 0.3 to 5% by weight (per chondroitin-14-monosulfuric acid repeating unit).
- a platinum atom of about 0.005 to 0.1), a chondroitin sulfate content of 80 to 96% by weight, a solubility in water of 20 C of 1 OmgZml or more, preferably 10 to 4 OmgZml, and the following physical property values.
- Solubility in various solvents soluble in water, hardly soluble in methanol, ethanol and ethers.
- Substance color The color of the freeze-dried product is white or pale yellow.
- Platinum release rate The half-life of platinum in physiological isotonic solutions is 3 to 48 hours.
- the platinum complex of the present invention is preferably administered parenterally to mammals including humans, and is used as an antitumor agent for treating tumors such as various cancers.
- Such parenteral preparations include aqueous preparations, suspensions, emulsions and the like for intravenous administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, topical administration and the like.
- the platinum complex of the present invention may be used as a pH adjuster (hydrochloric acid, sodium hydroxide, lactic acid, sodium lactate, sodium monohydrogen phosphate, sodium dihydrogen phosphate, etc.), isotonic, etc.
- Dissolving or suspending in a solution for injection distilled water for injection, glycerin water, propylene glycol water, etc.
- an agent sodium chloride, dextrose, etc.
- aseptically filtering and filling into an ampoule as an aqueous agent or the present invention
- mannitol, dextrin, cyclodextrin, etc. may be added to the platinum complex and filled into ampoules or vials as a powder (lyophilized product, crystal, microcrystal, etc.) to be used as a ready-to-dissolve injection. Is also good.
- the platinum complex of the present invention may be added to the emulsifier Tin, polysorbate 80, polyoxyethylene hydrogenated castor oil, etc.) and emulsify in water to give an injectable emulsion.
- the dosage of the above antitumor agent varies depending on the age, sex and disease state of the patient, but is usually about 0.01 mg to 1 Omg per day, 1 mg / kg body weight, and once or several times. It is desirable to administer in divided doses.
- FIG. 1 shows the results of electrophoresis of the platinum complexes of the present invention and a comparative example.
- 1 is a diac DACHP
- 2 is CSA
- 3 to 7 are electrophoretic images of CSA—DACHP1 to 5.
- FIG. 2 shows a high performance liquid chromatograph of CSA.
- FIG. 3 shows a high performance liquid chromatograph of the diac compound D ACHP.
- FIG. 4 shows a high performance liquid chromatograph of CSA—DACHP1.
- FIG. 5 shows a high performance liquid chromatograph of CSA—DACHP2.
- FIG. 6 shows the results of examining the antitumor activity of the platinum complexes of the present invention and the comparative example.
- FIG. 7 shows the results of examining the antitumor effect of the platinum complex of Comparative Example 2.
- FIG. 8 shows the in vivo trends of the platinum complex of the present invention.
- CSA chondroitin-14-monosulfate from cartilage (contains about% 5% chondroitin-14-monosulfate, average molecular weight 300000; manufactured by Seikagaku Corporation)
- Dissolve 500 mg in 100 ml of water add 0.446 ml (containing 25 mg) of the diaco-form DACHP prepared in Reference Example 1 and adjust the pH to 6 with 0.1 N-sodium hydroxide aqueous solution. The reaction was adjusted to 0 and reacted at 5 ° C in a dark room for 20 hours.
- reaction solution is dialyzed against distilled water to obtain low-molecular-weight unreacted reagents and secondary reagents.
- the organisms were removed, filtered through a 0.2 m pore size filtration membrane, and freeze-dried to obtain 554 mg of the platinum complex of the present invention (lot name: CSA-DACHP1).
- the solubility of the platinum complex is determined by adding purified water to the sample, stirring at 20 C for 20 hours, centrifuging for 5 minutes (300 Orpm), and quantifying the chondroitin sulfate content of the supernatant by the carbazole-sulfuric acid method. It was measured by:
- Example 1 the diako DACHP prepared in Reference Example 1 was added to 0.20 ml (12.5 mg), 0.893 ml (50 mg), and 50 Omg of the CSA aqueous solution, respectively. 1.786 ml (100 mg), 2.679 ml (15 Omg) or 3.571 ml (200 mg) were added and reacted to prepare platinum complexes with different platinum content and solubility in water. (Lot name: CSA-DACHP0, CSA-DACHP2, CSA-DACHP3, CSA-DACHP4, CSA-DACHP5 respectively). Table 1 shows the yield and analysis value of each platinum complex. t3, including CSA: Platinum content Solubility
- CSA—DACHP 1, 2, 3, 4 and 5 are dissolved in water to give concentrations of 20, 10, 5, 4 and 4 mg / ml, respectively, and then each of the cellulose acetate membranes for electrophoresis (81) is dissolved. SEPARAX, J ⁇ mitsu Co., Ltd.).
- CSA was dissolved in water to a concentration of 1.04 mgZml
- diaco-DACHP was dissolved in water to a concentration of 1.098 mg / ml.
- 21 and 81 were applied to the above films, respectively. did.
- electrophoresis was performed under the following conditions.
- Fig. 1 shows the results.
- 1 is the swimming image of the diako body D ACH P ⁇ 2
- C S A, and 3 to 7 are the swimming images of C S A—D AC H P 1 to 5.
- Each sample of CSA-DACHP 1 and 2 has a concentration of 1 mg, ml, ml58 has a concentration of 0.2 mg / ml, and diaco DACHP has a concentration of 0.28 mg Zml.
- 20 ⁇ l of the solution was injected into a high-performance liquid chromatography column.
- the column used was TSKge G4000PW XL manufactured by Tosoh Corporation, the solvent was 0.1 M sodium chloride solution, the flow rate was 0.5 ml / min, the detection was differential refraction (RI) and the absorbance at a wavelength of 21 Onm. Was measured and performed. The results are shown in FIGS.
- Each CSA-DA CHP sample has an absorption maximum at 250 and 300 nm, and the higher the amount of platinum, the greater the degree of absorption.
- Table 2 shows the results obtained by measuring the specific rotation of each of the platinum complexes of the above Examples and Comparative Examples (Comparative Example 2 will be described later).
- Example 1 CSA-DACHP1 -38.7
- Example 2 CSA-DACHP3 -32.0 Comparative Example CSA-DACHP4 -28.2
- chondroitin-mono-mono-sulfate (MW 30000) derived from whale cartilage (pH adjusted to 7.5 with an aqueous solution of 12 g / 15 OmU sodium hydroxide) was added to a commercially available chondroitinase ABC (Proteus vulgaris). - derived; Seikagaku Corporation) was added 1 000 units ZML, 3 7 220 minutes digested reaction solution e C, filtered Ri by the filtration membrane having a pore size of 0. 22 m, and lyophilized, con Droitin-1.4 monosulfate oligosaccharide 10.7 was obtained.
- Test Example 1 Anti-tumor effect
- L1210 cells (1 X 10 & ) were transplanted intraperitoneally with physiological saline to a predetermined concentration.
- the test solution obtained by dissolving the complex or D ACHP C 1 2 was administered on day 1 and 5 ⁇ after implantation, each survival time were examined survival rate.
- Table 4 shows the results. Controls received only physiological saline instead of the test solution.
- the antitumor activity of a platinum complex (CS-1 DACHP, CS-m-DACHP) similar to the platinum complex of the present invention, which was disclosed in JP-A-2-135201, was measured in the same manner as described above. Work
- T / C ⁇ %) represents the ratio of the survival time of the test solution-administered group to the survival time of the control group.
- JP-A-2-135201 Platinum complexes of Examples 1 and 2,
- Example 3 According to Example 1, mammals (whales) chondroitin-144 monosodium sulfate derived from cartilage (contains about 75% chondroitin-14-monosulfate, average molecular weight: 2200: Seikagaku Corporation) (Hereinafter referred to as CSA (W2200)) and chondroitin-14-monosodium sulfate derived from mammalian (cattle) tracheal cartilage (chondroitin-14-monosulfate approx.
- Test Example 3 (Anti-Tumor Activity) The lot prepared in Example 3 was tested according to Test Example 1. Table 7 shows the results.
- a specific chondroitin-4-monosulfate which has not been used in a conventional platinum complex using an acidic polysaccharide as a leaving group (carrier), is selected, and the platinum content is reduced.
- the platinum complex produced by adjusting the content to 5% by weight or less has remarkably improved solubility in water, and as a result, has improved antitumor activity.
- the platinum complex of the present invention has high organ selectivity for the liver, spleen and the like, and is particularly concentrated in the liver, and thus is useful as an antitumor agent for specifically suppressing tumors in these organs. Furthermore, since the release rate of platinum from the platinum complex is slow, it is a sustained-release antitumor agent that can maintain its antitumor effect for a long time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93908094A EP0636631A1 (en) | 1992-04-17 | 1993-04-15 | Platinum complex and antineoplastic agent |
CA002118217A CA2118217A1 (en) | 1992-04-17 | 1993-04-15 | Platinum complex and antitumor agent |
KR1019940703671A KR950700918A (ko) | 1992-04-17 | 1994-10-15 | 백금 착물 및 항종양제(platinum complex and antitumor agent) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/97744 | 1992-04-17 | ||
JP9774492 | 1992-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993021193A1 true WO1993021193A1 (en) | 1993-10-28 |
Family
ID=14200401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000483 WO1993021193A1 (en) | 1992-04-17 | 1993-04-15 | Platinum complex and antineoplastic agent |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0636631A1 (ja) |
KR (1) | KR950700918A (ja) |
AU (1) | AU3905293A (ja) |
CA (1) | CA2118217A1 (ja) |
WO (1) | WO1993021193A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772210B2 (en) | 2003-02-19 | 2010-08-10 | Stellar Pharmaceuticals Inc. | Cystitis treatment with high dose chondroitin sulfate |
JP5320296B2 (ja) * | 2007-10-01 | 2013-10-23 | 生化学工業株式会社 | 新規な低分子化コンドロイチン硫酸およびその用途 |
CN113398278A (zh) * | 2021-06-28 | 2021-09-17 | 山东大学 | 抗血管新生肽es2-af的硫酸软骨素化修饰物及其载顺铂的制备方法与应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005047308A1 (de) * | 2005-09-30 | 2007-04-05 | Martin-Luther-Universität Halle-Wittenberg | Platin(II)Verbindungen aus 2-substituierten Propan-1,3-diaminen zur Verwendung als Chemotherapeutikum |
CN109568336B (zh) * | 2018-12-29 | 2021-10-08 | 江苏靶标生物医药研究所有限公司 | 一种铂类化合物和硫酸软骨素的组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59116221A (ja) * | 1982-11-10 | 1984-07-05 | インコ、アロイス、インターナショナル、インコーポレーテッド | 白金またはパラジウム錯体 |
JPH02135201A (ja) * | 1988-11-16 | 1990-05-24 | Seikagaku Kogyo Co Ltd | 多糖を担体とする白金錯体、その製造法及び該白金錯体を有効成分とする抗腫瘍剤 |
JPH0480201A (ja) * | 1990-07-24 | 1992-03-13 | Seikagaku Kogyo Co Ltd | 燐脂質又は脂質結合グリコサミノグリカン |
JPH0480202A (ja) * | 1990-07-24 | 1992-03-13 | Seikagaku Kogyo Co Ltd | 燐脂質結合グリコサミノグリカン |
JPH0482836A (ja) * | 1990-07-24 | 1992-03-16 | Seikagaku Kogyo Co Ltd | 癌転移抑制剤 |
-
1993
- 1993-04-15 EP EP93908094A patent/EP0636631A1/en not_active Withdrawn
- 1993-04-15 CA CA002118217A patent/CA2118217A1/en not_active Abandoned
- 1993-04-15 AU AU39052/93A patent/AU3905293A/en not_active Abandoned
- 1993-04-15 WO PCT/JP1993/000483 patent/WO1993021193A1/ja not_active Application Discontinuation
-
1994
- 1994-10-15 KR KR1019940703671A patent/KR950700918A/ko not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59116221A (ja) * | 1982-11-10 | 1984-07-05 | インコ、アロイス、インターナショナル、インコーポレーテッド | 白金またはパラジウム錯体 |
JPH02135201A (ja) * | 1988-11-16 | 1990-05-24 | Seikagaku Kogyo Co Ltd | 多糖を担体とする白金錯体、その製造法及び該白金錯体を有効成分とする抗腫瘍剤 |
JPH0480201A (ja) * | 1990-07-24 | 1992-03-13 | Seikagaku Kogyo Co Ltd | 燐脂質又は脂質結合グリコサミノグリカン |
JPH0480202A (ja) * | 1990-07-24 | 1992-03-13 | Seikagaku Kogyo Co Ltd | 燐脂質結合グリコサミノグリカン |
JPH0482836A (ja) * | 1990-07-24 | 1992-03-16 | Seikagaku Kogyo Co Ltd | 癌転移抑制剤 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772210B2 (en) | 2003-02-19 | 2010-08-10 | Stellar Pharmaceuticals Inc. | Cystitis treatment with high dose chondroitin sulfate |
US8084441B2 (en) | 2003-02-19 | 2011-12-27 | Stellar Pharmaceuticals, Inc. | Cystitis treatment with high dose chondroitin sulfate |
US8334276B2 (en) | 2003-02-19 | 2012-12-18 | Stellar Pharmaceuticals Inc. | Cystitis treatment with high dose chondroitin sulfate |
US8778908B2 (en) | 2003-02-19 | 2014-07-15 | Stellar International Inc. | Cystitis treatment with high dose chondroitin sulfate |
JP5320296B2 (ja) * | 2007-10-01 | 2013-10-23 | 生化学工業株式会社 | 新規な低分子化コンドロイチン硫酸およびその用途 |
US9149572B2 (en) | 2007-10-01 | 2015-10-06 | Seikagaku Corporation | Chondroitin sulfate having decreased molecular weight and use thereof |
CN113398278A (zh) * | 2021-06-28 | 2021-09-17 | 山东大学 | 抗血管新生肽es2-af的硫酸软骨素化修饰物及其载顺铂的制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
KR950700918A (ko) | 1995-02-20 |
AU3905293A (en) | 1993-11-18 |
EP0636631A1 (en) | 1995-02-01 |
CA2118217A1 (en) | 1993-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900008442B1 (ko) | 가용성의 포스포릴화한 글루칸(glucan) | |
EP0302034B1 (en) | Novel heparin derivatives, a process for their preparation and their use in pharmaceuticals | |
US8828971B2 (en) | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders | |
AU2017385332A1 (en) | Composition of mannuronic dicarboxylic acid | |
US4900722A (en) | Methods and compositions for prophylactic and therapeutic treatment of infections | |
HUE028635T2 (en) | Sulfated polysaccharide compound and its preparation and use | |
US5760017A (en) | Cyclodextrin derivatives usable in particular for solubilizing hydrophobic chemical compounds such as medicaments and their preparation process | |
CA2434077A1 (en) | Cyclodextrin preparations | |
JPS595599B2 (ja) | プラチナ有機錯体、その製法および該錯体よりなる悪性腫瘍治療剤 | |
US3928581A (en) | Certain polymer-iron complexes for treatment of iron deficiency | |
HU185314B (en) | Process for producing water-soluble immunostimulant glyco-proteins from klebsiella pneumoniae | |
WO1993021193A1 (en) | Platinum complex and antineoplastic agent | |
CA2407065A1 (en) | A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component | |
EP0113123B1 (en) | Mannoglucan derivatives and process for preparing the same | |
CA2141845A1 (en) | Improved method for preparing soluble glucans | |
JPH0539224A (ja) | 抗炎症活性を有するコンドロイチン硫酸 コンプレツク ス,その製造方法およびそれを含有する医薬組成物 | |
WO1987007142A1 (en) | Novel complexes, process for their preparation, and medicinal use of them | |
JPH0129481B2 (ja) | ||
CA2027773C (en) | Treatment of shock by cyclodextrins and their derivatives | |
JP3156135B2 (ja) | 免疫賦活用活性物質及びその製造法 | |
JPH0129482B2 (ja) | ||
BR102019008173A2 (pt) | Processo de obtenção de bases de schiff biopoliméricas anfifílicas, base de schiff anfifílica e seu uso | |
KR840000801B1 (ko) | 백금 디아민 착염의 제조방법 | |
JPH04202197A (ja) | 還元ヘキサ―n―アセチル―キトヘキサオースを有効成分とする抗腫瘍剤 | |
JPS582301A (ja) | 多糖体およびその製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2118217 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993908094 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993908094 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993908094 Country of ref document: EP |